These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15548406)

  • 21. Use of misoprostol in third stage of labour.
    Khan R; Sharma S
    Lancet; 2002 Feb; 359(9307):708-9; author reply 709-10. PubMed ID: 11879892
    [No Abstract]   [Full Text] [Related]  

  • 22. Misoprostol for preventing and treating postpartum hemorrhage in the community: a closer look at the evidence.
    Oladapo OT
    Int J Gynaecol Obstet; 2012 Nov; 119(2):105-10. PubMed ID: 22968139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should we be using misoprostol to prevent postpartum haemorrhage?
    Pract Midwife; 2013 May; 16(5):9. PubMed ID: 23789247
    [No Abstract]   [Full Text] [Related]  

  • 24. Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India.
    Patted SS; Goudar SS; Naik VA; Bellad MB; Edlavitch SA; Kodkany BS; Patel A; Chakraborty H; Derman RJ; Geller SE
    J Matern Fetal Neonatal Med; 2009 Jan; 22(1):24-8. PubMed ID: 19089777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for scale-up of community-based misoprostol distribution programs.
    Robinson N; Kapungu C; Carnahan L; Geller S
    Int J Gynaecol Obstet; 2014 Jun; 125(3):285-8. PubMed ID: 24680582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, randomized, placebo-controlled trial of misoprostol and routine uterotonics for the prevention of postpartum hemorrhage.
    Fawole AO; Sotiloye OS; Hunyinbo KI; Umezulike AC; Okunlola MA; Adekanle DA; Osamor J; Adeyanju O; Olowookere OO; Adekunle AO; Singata M; Mangesi L; Hofmeyr GJ
    Int J Gynaecol Obstet; 2011 Feb; 112(2):107-11. PubMed ID: 21130446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ethical considerations in industry-sponsored multiregional clinical trials.
    Ibia E; Binkowitz B; Saillot JL; Talerico S; Koerner C; Ferreira I; Agarwal A; Metz C; Maman M
    Pharm Stat; 2010; 9(3):230-41. PubMed ID: 20824884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sublingual misoprostol as an adjunct to oxytocin during cesarean delivery in women at risk of postpartum hemorrhage.
    Chaudhuri P; Majumdar A
    Int J Gynaecol Obstet; 2015 Jan; 128(1):48-52. PubMed ID: 25277789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women.
    Chaudhuri P; Biswas J; Mandal A
    Int J Gynaecol Obstet; 2012 Feb; 116(2):138-42. PubMed ID: 22100204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trial.
    Walraven G; Blum J; Dampha Y; Sowe M; Morison L; Winikoff B; Sloan N
    BJOG; 2005 Sep; 112(9):1277-83. PubMed ID: 16101608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Home use of misoprostol to prevent PPH. Editor's Comment.
    Fortney JA
    Int J Gynaecol Obstet; 2010 Mar; 108(3):268. PubMed ID: 20053401
    [No Abstract]   [Full Text] [Related]  

  • 32. Misoprostol: an essential medicine for managing postpartum hemorrhage in low-resource settings?
    Rushwan H
    Int J Gynaecol Obstet; 2011 Sep; 114(3):209-10. PubMed ID: 21745664
    [No Abstract]   [Full Text] [Related]  

  • 33. Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: cost-effectiveness, mortality, and morbidity reduction analysis.
    Sutherland T; Meyer C; Bishai DM; Geller S; Miller S
    Int J Gynaecol Obstet; 2010 Mar; 108(3):289-94. PubMed ID: 20079493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive rectal misoprostol versus oxytocin infusion for prevention of postpartum hemorrhage in women at risk: a randomized controlled trial.
    Badejoko OO; Ijarotimi AO; Awowole IO; Loto OM; Badejoko BO; Olaiya DS; Fatusi AO; Kuti O; Orji EO; Ogunniyi SO
    J Obstet Gynaecol Res; 2012 Nov; 38(11):1294-301. PubMed ID: 22612662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Council for International Organizations and Medical Sciences (CIOMS) guidelines on ethics of clinical trials.
    Macrae DJ
    Proc Am Thorac Soc; 2007 May; 4(2):176-8, discussion 178-9. PubMed ID: 17494727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial on the value of misoprostol for the treatment of retained placenta in a low-resource setting.
    van Beekhuizen HJ; Tarimo V; Pembe AB; Fauteck H; Lotgering FK
    Int J Gynaecol Obstet; 2013 Sep; 122(3):234-7. PubMed ID: 23791153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind randomized controlled trial of oral misoprostol and intramuscular syntometrine in the management of the third stage of labor.
    Ng PS; Lai CY; Sahota DS; Yuen PM
    Gynecol Obstet Invest; 2007; 63(1):55-60. PubMed ID: 16940738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rethinking WHO Guidance.
    Kerr NL
    J R Soc Med; 2012 Nov; 105(11):454-5; author reply 455-6. PubMed ID: 23257964
    [No Abstract]   [Full Text] [Related]  

  • 39. Women's health in women's hands: a pilot study assessing the feasibility of providing women with medications to reduce postpartum hemorrhage and sepsis in rural Tanzania.
    Webber GC; Chirangi B
    Health Care Women Int; 2014; 35(7-9):758-70. PubMed ID: 24786175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International collaborative trials, placebo controls and The Declaration of Helsinki: need for clarification in paragraph 32.
    Malik AY; Ghafoor F
    Indian J Med Ethics; 2012; 9(1):13-8. PubMed ID: 22319846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.